Advanced search
Publication Cover
Clinical Pharmacology: Advances and Applications Volume 13, 2021 - Issue
Submit an article Journal homepage
144
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19

Prasan Kumar Panda1 Department of Medicine (Infectious Disease Division), All India Institute of Medical Sciences (AIIMS), Rishikesh, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3008-7245
ORCID Icon,
Budha O Singh1 Department of Medicine (Infectious Disease Division), All India Institute of Medical Sciences (AIIMS), Rishikesh, India
,
Bikram Moirangthem1 Department of Medicine (Infectious Disease Division), All India Institute of Medical Sciences (AIIMS), Rishikesh, India
,
Yogesh Arvind Bahurupi2 Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
,
Sarama Saha3 Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
,
Girraj Saini4 Department of Nursing, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
,
Minakshi Dhar1 Department of Medicine (Infectious Disease Division), All India Institute of Medical Sciences (AIIMS), Rishikesh, India
,
Mukesh Bairwa1 Department of Medicine (Infectious Disease Division), All India Institute of Medical Sciences (AIIMS), Rishikesh, India
,
Venkatesh Srinivasa Pai1 Department of Medicine (Infectious Disease Division), All India Institute of Medical Sciences (AIIMS), Rishikesh, India
,
Ankit Agarwal5 Department of Critical Care Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
,
Girish Sindhwani6 Department of Pulmonary Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
,
Shailendra Handu7 Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
&
Ravi Kant8 Department of General Surgery, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
 show all
Pages 185-195 | Published online: 29 Sep 2021

References

  • Centers for Disease Control and Prevention. Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19. US Dept Health Hum Serv. 2020;2019:1–6.
  • BanerjeeD, PopoolaJ, ShahS, SterIC, QuanV, PhanishM. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020;97(6):1076–1082. doi:10.1016/j.kint.2020.03.01832354637
  • ZambranoLD, EllingtonS, StridP, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status — United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(44):1641–1647. doi:10.15585/mmwr.mm6944e333151921
  • WhittakerA, AnsonM, HarkyA. Neurological manifestations of COVID-19: a systematic review and current update. Acta Neurol Scand. 2020;142(1):14–22. doi:10.1111/ane.1326632412088
  • HenryBM, de OliveiraMHS, BenoitS, PlebaniM, LippiG. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021–1028. doi:10.1515/cclm-2020-036932286245
  • AgarwalA, ChenA, RavindranN, ToC, ThuluvathPJ. Gastrointestinal and liver manifestations of COVID-19. J Clin Exp Hepatol. 2020;10(3):263–265. doi:10.1016/j.jceh.2020.03.00132405183
  • SachdevaM, GianottiR, ShahM, et al. Cutaneous manifestations of COVID-19: report of three cases and a review of literature. J Dermatol Sci. 2020;98(2):75–81. doi:10.1016/j.jdermsci.2020.04.01132381430
  • LiuPP, BletA, SmythD, LiH. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020;142(1):68–78. doi:10.1161/CIRCULATIONAHA.120.04754932293910
  • BikdeliB, MadhavanMV, JimenezD, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950–2973. doi:10.1016/j.jacc.2020.04.03132311448
  • LiuJ, CaoR, XuM, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):16. doi:10.1038/s41421-020-0156-0
  • Indian Council of Medical Research [Internet]. Advisory on the use of hydroxychloroquine as prophylaxis for SARS-CoV-2 infection [Internet]; 2020:1–3. Available from:https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf. Accessed 97, 2021.
  • ZhouD, DaiS-M, TongQ. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020;75(7):1667–1670. doi:10.1093/jac/dkaa11432196083
  • GaoJ, TianZ, YangX. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73. doi:10.5582/bst.2020.0104732074550
  • HorbyPW, MafhamM, BellJL; RECOVERY Collaborative Group. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–1352. doi:10.1016/S0140-6736(20)32013-433031764
  • CaoB, WangY, WenD, et al. a trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/NEJMoa200128232187464
  • KhaliliJS, ZhuH, MakNSA, YanY, ZhuY. Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19. J Med Virol. 2020;92(7):740–746. doi:10.1002/jmv.2579832227493
  • SandersJM, MonogueML, JodlowskiTZ, CutrellJB. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824–1836.32282022
  • KapoorM, PandaPK, MohantyV. Pharmacotherapy for COVID-19: a ray of hope. IntechOpen. 2021. Available from:: https://www.intechopen.com/online-first/pharmacotherapy-for-covid-19-a-ray-of-hope. Accessed September 7, 2021.
  • LippiG, WongJ, HenryBM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020;130(4):304–309.32231171
  • COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. Available from:https://www.covid19treatmentguidelines.nih.gov/. Accessed 97, 2021.
  • The U.S. Food and Drug Administration. FDA approves first treatment for COVID-19; 2020. Available from:https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19. Accessed 530, 2021.
  • WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511. doi:10.1056/NEJMoa202318433264556

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.